The effect of androgen supplementation therapy on the prostate

References

• Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983;56:1278–81
   Google Scholar
• Ferrini RL, Barrett-Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 1998; 147:750–4
   Google Scholar
• Purifoy FE, Koopmans LH, Mayes DM. Age differences in serum androgen levels in normal adult males. Hum Biol 1981;53:499–511
   Google Scholar
• England B, Wojno KJ, Beduschi MC, Giacherio DA. Changes in serum testosterone (T), free PSA, and percent free PSA over time in a healthy aging population followed longitudinally for 9 years. J Urol 1997;157:54
   Google Scholar
• Morley JE, Kaiser FE, Perry HM III, Patrick P, Morley PM, Stauber PM, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410–13
   Google Scholar
• Pearson U, Blackman MR, Metter EJ, Waclawiw Z, Carter HB, Herman JM. Effect of age and cigarette smoking on longitudinal changes in androgens and SHBG in healthy males. In Proceed- ings of the 77th Meeting of The Endocrine Society. Washington, DC: The Endocrine Society, 1995:322
   Google Scholar
• Krithivas K, Yurgalevitch SM, Mohr BA, Wilcox CJ, Batter SJ, Brown M, et al. Evidence that the CAG repeat in the androgen receptor is associated with age related decline in serum androgen levels in men. J Endocrinol 1999;162:137–42
   Google Scholar
• Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardio- vascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 1997;146:609–17
   Google Scholar
• Harman M, Metter J, Toben JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2000;86:724–31
   Google Scholar
• Lerner SE, Melman A, Christ GJ. A review of erectile dysfunction: new insights and more questions. J Urol 1993;149:1246–55
   Google Scholar
• Broderick GA. Impotence. J Urol 1996;155:549–50
   Google Scholar
• Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000;85:2839–53
   Google Scholar
• Handelsman DJ, Mackey MA, Howe C, Turner L, Conway AJ. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol (Oxf) 1997;47:311–16
   Google Scholar
• Frey H, Aakvaag A, Saanum D, Falch J. Bio- availability of oral testosterone in males. Eur J Clin Pharmacol 1979;16:345–9
   Google Scholar
• National Disease and Therapeutic Index, 2003. Plymouth Meeting, PA, IMS America, Ltd., 2003
   Google Scholar
• Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987; 8:1–28
   Google Scholar
• Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251–65
   Google Scholar
• Joseph IB, Isaacs JT. Potentiation of the anti- angiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen- responsive prostatic cancers. Cancer Res 1997;57:1054–7
   Google Scholar
• Hiramatsu M, Kashimata M, Minami N, Sato A, Murayama M. Androgenic regulation of epidermal growth factor in the mouse ventral prostate. Biochem Int 1988;17:311–17
   Google Scholar
• Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 1991;51:2780–5
   Google Scholar
• Kyprianou N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989;3:1515–22
   Google Scholar
• Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology 1990; 127:2963–8
   Google Scholar
• Peehl D, Cohen P, Rosenfeld RG. The insulin- like growth factor system in the prostate. World J Urol 1995;13:306–11
   Google Scholar
• Sherwood E, Fong CJ, Lee C, Kozlowski JM. Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate. Endocrinology 1992;130:2955–63
   Google Scholar
• Story M. Regulation of prostate growth by fibroblast growth factors. World J Urol 1995;13:297–305
   Google Scholar
• Djakiew D. Role of nerve growth factor-like protein in the paracrine regulation of prostate growth. J Androl 1992;13:476–87
   Google Scholar
• Joseph IB, Nelson JB, Denmeade SR, Isaacs JT.Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997;3:2507–11
   Google Scholar
• Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997;57:141–6
   Google Scholar
• Costa-Pereira AP, Cotter TG. Molecular and cellular biology of prostate cancer – the role of apoptosis as a target for therapy. Prostate Cancer Prostatic Dis 1999;2:126–39
   Google Scholar
• Ozen M, Pathak S. Genetic alterations in human prostate cancer: a review of current literature. Anticancer Res 2000;20:1905–12
   Google Scholar
• Raivio T, Santti H, Schatzl G, Gsur A, Haidinger G, Palvimo JJ, et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate 2003;55:194–8
   Google Scholar
• Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, et al. High- grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47:52–8
   Google Scholar
• Gann PH, Klein KG, Chatterton RT, Ellman AE, Grayhack JT, Nadler RB, et al. Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates. Prostate 1999;40:248–55
   Google Scholar
• Schatzl G, Madersbacher S, Haitel A, Gsur A, Preyer M, Haidinger G, et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169:1312–15
   Google Scholar
• Gallagher RP, Kutynec CL. Diet, micronutrients and prostate cancer: a review of the evidence. Can J Urol 1997;4:22–7
   Google Scholar
• Rohan TE, Howe GR, Burch JD, Jain M. Dietary factors and risk of prostate cancer: a case-control study in Ontario, Canada. Cancer Causes Control 1995;6:145–54
   Google Scholar
• Horton R. Benign prostatic hyperplasia: a disorder of androgen metabolism in the male. J Am Geriatr Soc 1984;32:380–5
   Google Scholar
• Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995;16:271–321
   Google Scholar
• Shaneyfelt T, Husein R, Bubley G, Mantzoros CS.Hormonal predictors of prostate cancer: a meta- analysis. J Clin Oncol 2000;18:847–53
   Google Scholar
• Eaton NE, Reeves GK, Appleby PN, Key TJ.Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1999;80:930–4
   Google Scholar
• Slater S, Oliver RT. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000;17:431–9
   Google Scholar
• Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling G, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169:1670–5
   Google Scholar
• Marin P. Testosterone and regional fat distribution. Obes Res 1995;3(Suppl 4):609S–12S
   Google Scholar
• Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997;49:191–6
   Google Scholar
• Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85:2670–7
   Google Scholar
• Canale D, Mais V, Turchi P, Andreini F, Melis GB, Menchini-Fabris GF. Ultrasound monitoring of testis and prostate maturation in hypogonadotropic hypogonadic males during gonadotropin-releasing hormone treatment. Fertil Steril 1990;53:537–40
   Google Scholar
• Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994;40:341–9
   Google Scholar
• Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997;82:3793–6
   Google Scholar
• Tenover JS. Effects of testosterone supplement- ation in the aging male. J Clin Endocrinol Metab 1992;75:1092–8
   Google Scholar
• Holmang S, Marin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate- specific antigen concentration in eugonadal middle-aged men. Prostate 1993;23:99–106
   Google Scholar
• Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82:1661–7
   Google Scholar
• Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15:212–15
   Google Scholar
• Kaufman J, Steidle C, Dula E, Wells G, Susset J. Long-term efficacy and safety of topical 1% testosterone gel (T-gel) in hypogonadal men. Int J Imp Res 2002;14:521
   Google Scholar
• Kaufman J. Safety and efficacy of a testosterone (T) gel in a geriatric population. J Urol 2002;167:280
   Google Scholar
• Fowler JE Jr, Whitmore WF Jr. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 1982;49:1373–7
   Google Scholar
• Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990; 143:742–6
   Google Scholar
• Sakr W, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP. High grade pro- static intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo 1994;8:439–43
   Google Scholar
• Morgentaler A, Bruning CO III, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. J Am Med Assoc 1996;276:1904–6
   Google Scholar
• Billis A. Latent carcinoma and atypical lesions of prostate. An autopsy study. Urology 1986;28:324–9
   Google Scholar
• Takahashi S, Shirai T, Hasegawa R, Imaida K, Ito N. Latent prostatic carcinomas found at autopsy in men over 90 years old. Jpn J Clin Oncol 1992; 22:117–21
   Google Scholar
• Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol 1980;14:29–35
   Google Scholar
• Jackson JA, Waxman J, Spiekerman AM. Prostatic complications of testosterone replacement therapy. Arch Intern Med 1989;149:2365–6
   Google Scholar
• Loughlin KR, Richie JP. Prostate cancer after exogenous testosterone treatment for impotence. J Urol 1997;157:1845
   Google Scholar
• Ferri M, Norman RW. Prostate cancer in a hypogonadal male receiving androgen supple- mentation. Can J Urol 2000;7:1055–6
   Google Scholar
• Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypo- gonadal men treated with testosterone replace- ment. J Androl 2002;23:922–6
   Google Scholar
• Ludwig G. [PADAM from the urologic view- point]. Urologe A 2000;39:407–10
   Google Scholar
• Morales A. Androgen replacement therapy and prostate safety. Eur Urol 2002;41:113–20
   Google Scholar
• Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003;24:299–311
   Google Scholar
• Morley JE, Perry HM III, Kaiser FE, Kraenzle D, Jensen J, Houston K, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993;41:149–52
   Google Scholar
• Svetec DA, Canby ED, Thompson IM, Sabanegh ES Jr. The effect of parenteral testosterone replace- ment on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997;158:1775–7
   Google Scholar
• Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol (Oxf) 2001;54:437–45
   Google Scholar
• Kaufman J, Graydon RJ. Androgen administration in hypogonadal men after radical prostatectomy for their prostate cancer. J Urol 2003;169:378
   Google Scholar
• Cooper CS, MacIndoe JH, Perry PJ, Yates WR, Williams RD. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. J Urol 1996;156:438–41,discussion 441–2
   Google Scholar